Vipera berus
Vipera berus

Pressmeddelande -

Scandinavian Biopharma enters into an exclusive agreement with Flynn Pharma for ViperaTAb

Scandinavian Biopharma today announces that the company has entered into an exclusive agreement with Flynn Pharma for the viper antivenom ViperaTAb.

Under the new agreement, Scandinavian Biopharma will have exclusive rights to service and make ViperaTAb available for emergency use in the Nordics, Baltic States and Germany.

“We are very pleased to strengthen our portfolio with an important antivenom for Northern Europe” says Björn Sjöstrand, CEO at Scandinavian Biopharma. “

ViperaTAb is not registered in the European Union but is available under special permission. 

For more information, please contact:
Björn Sjöstrand, CEO: +46 727-125 120, bjorn.sjostrand@scandinavianbiopharma.se

Ämnen

Scandinavian Biopharma

Scandinavian Biopharma is a Swedish research-based biotech company specialist in marketing and sales of vaccines, immunoglobulin's, biodefense, antidotes and diagnostic tests.

Research and development is mainly focused on development of a new oral traveler’s diarrhea vaccine in collaboration with PATH Vaccine Solutions and University of Gothenburg.

www.scandinavianbiopharma.se

Kontakter

Björn Sjöstrand

Björn Sjöstrand

Presskontakt VD +46 (0)72 712 51 20

Relaterat innehåll

Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug

Scandinavian Biopharma expands its product portfolio with an immunosuppressive drug

Scandinavian Biopharma has expanded its product offering to include Neovii’s GRAFALON®. This product is unique since it is registered for use in both organ and stem-cell transplantation. GRAFALON® is used to suppress immune reactions leading to organ rejection or GvHD.

Growth Scadinavian Biopharma 2009-2016

Scandinavian Biopharma continues to grow - 2016 was another successful year

2016 was another successful year with continued strong growth for Scandinavian Biopharma. For the distribution business, which are conducted through the subsidiary Scandinavian Biopharma Distribution, revenue growth landed at impressive 43%.

Growth Scandinavian Biopharma 2009-2017

Scandinavian Biopharma is once again looking back on a highly successful business year

We are very proud to report completion of a large Phase I/II child study in Bangladesh, we were awarded 30 MSEK from Horizon 2020 SME and we kick-started a Phase IIB study on travellers to Benin. We have strengthened our organization and continued to grow our distribution business.

Vi är ett forskningsbaserat biotechföretag fast beslutna att ge människor i hela världen ett längre och bättre liv.

Vi utvecklar det första vaccinet i världen mot diarré orsakad av ETEC för att skydda både barn och vuxna i endemiska länder och resenärer till högriskdestinationer.

Vi distribuerar ett brett sortiment av biologiska specialistläkemedel med fokus på vacciner och immunglobuliner.

www.scandinavianbiopharma.se

Vår information på mynewsdesk riktar sig till journalister och media.

Scandinavian biopharma
Industrivägen 1, vån 4
171 48 Solna
Sverige
Hemsida
LinkedIn-sida